DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
Gupta A., Love S., Schuh A., Shanyinde M., Larkin JM., Plummer R., Nathan PD., Danson S., Ottensmeier CH., Lorigan P., Collins L., Wise A., Asher R., Lisle R., Middleton MR.